The Evolutionary Landscape of Treatment for BRAF^V600E Mutant Metastatic Colorectal Cancer.

ABSTRACT: The BRAF^V600E mutation is found in 8-10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months. At present, besides immune checkpoint inhibitors (CPIs) for those tumors with concomitant MSI-H status, recommended treatment options include cytotoxic chemotherapy + anti-VEGF in the first line setting, and a combination of EGFR and a BRAF inhibitor (cetuximab plus encorafenib) in second line. However, even with the latter targeted approach, acquired resistance limits the possibility of more than an incremental benefit and survival is still dismal. In this review, we discuss current treatment options for this subset of patients and perform a systematic review of ongoing clinical tri

SUBMITTER: Mauri G 

PROVIDER: S-EPMC7795863 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature